• We have a fully funded Phase 3 clinical program in a global partnership for Pracinostat worth up to $464 million.

    Read Our 2017 Annual Review

  • Emerging data positions our second drug candidate, a highly differentiated PI3K delta inhibitor, toward a pivotal study in the coming year.

    Read Our 2017 Annual Review

  • Our newest asset, a selective CDK inhibitor with potent inhibition of CDK9, addresses resistance to potential blockbuster drug Venclexta.

    Read Our 2017 Annual Review

  • We are led by a world-class management team with proven experience in oncology drug development, from discovery to approval.

    Read Our 2017 Annual Review

LATEST NEWS

MEI Pharma Interim Data Review Supports Continuation of Clinical Study Evaluating ME-344 in Patients with Breast Cancer​
Press Release 


MEI Pharma Reports Second Quarter Fiscal Year 2018 Results​​
Press Release 


Helsinn Group and MEI Pharma Announce that Pracinostat has Received Orphan Drug Designation from the European Medicines Agency for the Treatment of Acute Myeloid Leukemia (AML)​
Press Release 


MEI Pharma Announces FDA Clearance of Investigational New Drug Application for CDK Inhibitor Voruciclib​
Press Release 


=